Axcella Health Inc (NASDAQ:AXLA) Director David R. Epstein purchased 14,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were acquired at an average cost of $3.55 per share, for a total transaction of $49,700.00. Following the purchase, the director now owns 52,293 shares of the company’s stock, valued at $185,640.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
AXLA stock traded up $0.36 during mid-day trading on Monday, reaching $4.36. 109,455 shares of the stock traded hands, compared to its average volume of 33,858. The company has a current ratio of 11.75, a quick ratio of 11.75 and a debt-to-equity ratio of 0.33. Axcella Health Inc has a one year low of $2.76 and a one year high of $15.99. The business has a 50-day moving average price of $4.53 and a two-hundred day moving average price of $7.81.
Axcella Health (NASDAQ:AXLA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.75) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.04). As a group, analysts anticipate that Axcella Health Inc will post -3.65 earnings per share for the current year.
Hedge funds have recently bought and sold shares of the business. Artal Group S.A. bought a new position in Axcella Health during the second quarter valued at $3,628,000. Vanguard Group Inc. bought a new position in Axcella Health during the second quarter valued at $499,000. BlackRock Inc. bought a new position in Axcella Health during the second quarter valued at $667,000. Morgan Stanley bought a new position in Axcella Health during the second quarter valued at $56,000. Finally, Northern Trust Corp bought a new position in Axcella Health during the second quarter valued at $90,000. Institutional investors and hedge funds own 62.41% of the company’s stock.
A number of equities research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Axcella Health from a “hold” rating to a “sell” rating in a research note on Friday, October 18th. ValuEngine raised shares of Axcella Health from a “hold” rating to a “buy” rating in a research note on Friday, October 4th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $22.00.
Axcella Health Company Profile
There is no company description available for Axcella Health Inc
Recommended Story: 52-week highs
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.